How to define bifurcation lesion complexity and how to successfully perform percutaneous treatment

M J Grundeken1, R P Kraak, R J De Winter

  • 1Amsterdam Heart Center, Academic Medical Center, Amsterdam, The Netherlands - m.j.grundeken@amc.uva.nl.

Insights

Percutaneous coronary interventions (PCI) for bifurcation lesions have improved, but high-risk subtypes still pose challenges. Future research should focus on dedicated devices for these complex cases, including distal left main bifurcations.

Area of Science:

  • Interventional Cardiology
  • Cardiovascular Disease Research

Background:

  • Percutaneous coronary interventions (PCI) for bifurcation lesions historically had lower success rates and higher complications than non-bifurcation lesions.
  • Advancements in stent design and specific bifurcation techniques have improved outcomes over the last decade.

Purpose of the Study:

  • To evaluate the current status of PCI for coronary bifurcation lesions.
  • To identify high-risk bifurcation lesion subtypes that still present challenges.
  • To guide future research and device development for complex coronary bifurcations.

Main Methods:

  • Review of recent studies and clinical outcomes related to PCI of coronary bifurcation lesions.
  • Analysis of factors contributing to adverse cardiac events in specific bifurcation lesion subtypes.
  • Identification of areas for future technological and procedural development.

Main Results:

  • While overall PCI for bifurcation lesions has improved, certain subtypes remain associated with increased risk of adverse cardiac events.
  • Distal left main bifurcations represent a particularly high-risk subgroup requiring further attention.

Conclusions:

  • Despite technological advancements, PCI for specific high-risk coronary bifurcation lesions, such as distal left main, still requires improved strategies.
  • Future efforts should concentrate on developing dedicated bifurcation devices and techniques for these challenging patient groups.

Related Concept Videos

Peripheral Artery Disease III: Interprofessional Care01:27

Peripheral Artery Disease III: Interprofessional Care

Peripheral Artery Disease (PAD) is characterized by narrowed arteries that diminish blood flow to the extremities. Effective management of PAD requires an interprofessional approach involving various healthcare professionals. The critical aspects of interprofessional care for PAD patients focus on risk factor modification, drug therapy, exercise therapy, nutrition therapy, critical limb ischemia care, and interventional radiology and surgical procedures.The primary treatment goal for PAD...
606
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
421
Acute Coronary Syndrome IV: Interprofessional Care01:28

Acute Coronary Syndrome IV: Interprofessional Care

IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
487
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
602
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
439
Acute Coronary Syndrome I: Introduction01:30

Acute Coronary Syndrome I: Introduction

Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.8K